Literature DB >> 28168728

Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Thomas Vanhove1,2, Pieter Annaert3, Dirk R J Kuypers1,2.   

Abstract

Entities:  

Keywords:  4β-hydroxycholesterol; CYP3A; bodyweight; kidney transplantation; tacrolimus

Mesh：

Substances：

Year:  2017        PMID： 28168728      PMCID： PMC5427232          DOI： 10.1111/bcp.13249

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2016-12-22       Impact factor: 4.335

2.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

3.  Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study.

Authors:  Elisabet Størset; Anders Åsberg; Morten Skauby; Michael Neely; Stein Bergan; Sara Bremer; Karsten Midtvedt
Journal:  Transplantation       Date:  2015-10       Impact factor: 4.939

4.  Effect of Statin Treatment on Plasma 4β-Hydroxycholesterol Concentrations.

Authors:  Linda Björkhem-Bergman; Hanna Nylén; Mats Eriksson; Paolo Parini; Ulf Diczfalusy
Journal:  Basic Clin Pharmacol Toxicol       Date:  2016-01-14       Impact factor: 4.080

Review 5.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

6.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

7.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Authors:  Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2015-10-12       Impact factor: 16.971
  7 in total
  2 in total

1.  Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.

Authors:  Elisabet Størset; Kristine Hole; Karsten Midtvedt; Stein Bergan; Espen Molden; Anders Åsberg
Journal:  Br J Clin Pharmacol       Date:  2017-04-03       Impact factor: 4.335

2.  Pretransplant 4β-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.

Authors:  Thomas Vanhove; Mahmoud Hasan; Pieter Annaert; Stefan Oswald; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2017-07-14       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.